Alteration of Gut Microbiota and Its Impact on Immune Response in Patients with Chronic HBV Infection: A Review
Yeshimebet Kassa,Yihenew Million,Alemu Gedefie,Feleke Moges
DOI: https://doi.org/10.2147/IDR.S305901
2021-07-06
Infection and Drug Resistance
Abstract:Yeshimebet Kassa, 1 Yihenew Million, 2 Alemu Gedefie, 1 Feleke Moges 2 1 Department of Medical Laboratory Sciences, College of Medicine and Health Science, Wollo University, Dessie, Ethiopia; 2 Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia Correspondence: Yeshimebet Kassa Department of Medical Laboratory Science, College of Medicine and Health Sciences, Wollo University, PO.BOX: 1145, Dessie, Ethiopia Tel +251- 915778098 Fax +251 333115250 Email Chronic hepatitis B virus infection is a source of substantial global health problems, particularly in economically underdeveloped and/or developing countries. It is the primary cause of severe liver disorders such as liver fibrosis, cirrhosis, and hepatocellular carcinoma. The liver is connected by the bile duct to the small intestine that carries bile produced in the liver to the intestine. The liver is the initial organ exposed to materials originating from the gut including dietary compounds, bacteria, and their products. Human intestines harbor a wide diversity of the community of microbes which are collectively termed as gut microbiota. In chronic infection with the hepatitis B virus, microbial alteration of the gut is a source of systemic immune activation. Besides, gut permeability is altered in hepatitis B virus-infected patients with an increased bacterial translocation and endotoxin load in the portal vein that caused toll-like receptor activation in the liver, which facilitates immune-mediated liver injury. Toll-like receptors further triggered the host-wide inflammatory response by inducing signaling cascades such as nuclear factor-kappa B-linked pathways and by accelerating cytokine secretion like tumor necrosis factor-alpha, which evokes chronic inflammation and leads to liver lesion formation, fibrosis progression, and cirrhosis and hepatocellular carcinoma development. In conclusion, changes in intestinal flora play an important role in encouraging the production of chronic infection with the hepatitis B virus. Therefore, careful attention should be given to the maintenance of intestinal microecology of patients which can provide a sound foundation for the treatment of chronic infection with the hepatitis B virus. Keywords: hepatitis B virus, gut microbiota, immune response Chronic hepatitis B (CHB) infection is a global epidemic disease that results from hepatitis B virus (HBV) infection and may progress to severe liver disorders, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. 1 Hepatitis B virus (HBV) is a noncytopathic, hepatotropic virus of the family Hepadna viridae; it is an enveloped virus with circular partially double-stranded DNA representing the highly compact organization. HBV is the smallest known DNA virus, having a spherical shape of approximately 42 nm in diameter and a genomic length of about 3200 base pairs. 2 , 3 Hepatitis B virus has four overlapping open reading frames: preC/C that encodes for e antigen (HBeAg) and core protein (HBcAg), P for polymerase (reverse transcriptase), S for surface proteins, and X for a transcriptional trans-activator protein. HBV is replicated by reverse transcription of pre-genomic RNA, which is transcribed from the covalently closed-circular form of HBV DNA in the hepatocyte nucleus by cellular RNA polymerase II. Sequence heterogeneity is a characteristic of HBV since POL cannot proofread. 4 According to phylogenetic analysis, HBV can be classified into ten, A-J, based upon an inter-group divergence. 4 , 5 HBV surface antigen (HBsAg) indicates an acute or chronic infection, and it is commonly regarded as a serological marker for HBV infection. Infection is considered chronic if it persists for greater than 6 months. HBsAg disappearance and HBV surface antibody (HBsAb) emergence indicate the recovery from infection and the development of HBV immunity. 6 HBV core antigen (HBcAg) consists of the core particle of the virus that is surrounded by HBsAg. HBV e antigen (HBeAg), the soluble secretory form of HBcAg, serves as an important serological marker indicating viral replication. HBeAg to e antibody (HBeAb) conversion suggests host immune control and low replication of HBV. 7 Adult infections have a relatively low chronicity rate (around 5%); typically, neonatal infections have a high persistence rate. 8–10 Chronic infections are often asymptomatic, but carriers of HBV are at risk of developing lif -Abstract Truncated-
pharmacology & pharmacy,infectious diseases